Tranzyme
Durham
About Tranzyme
Tranzyme Pharma is a biopharmaceutical company focused on the discovery, development, and commercialization of mechanism-based therapies. The company currently has programs for gastrointestinal motility disorders and retains worldwide rights for these programs. The company’s product portfolio includes, TZP-101, for the treatment of post-operative ileus and severe gastroparesis; and TZP-301, for the treatment of obesity and metabolic syndrome. Tranzyme Pharma is based in North Carolina, United States.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $20.0M
- Last round: Series Unknown (Nov 2007)
- Website: tranzyme.com
Industries & Categories
Biotechnology, Medical, Therapeutics
Canonical: https://fsome.com/organization/tranzyme-1251877 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.